Identifying predictors of outcomes in COPD exacerbations
Risk Stratifying COPD Exacerbations: a Prospective Study
This study is trying to see if certain signs and symptoms can help predict how well people with COPD will do during flare-ups, especially in Asian patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Pamela Youde Nethersole Eastern Hospital Academic / other |
| Locations | 2 sites (Hong Kong, Other and 1 other locations) |
| Trial ID | NCT05852327 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify clinical characteristics at presentation that can predict outcomes for patients experiencing exacerbations of Chronic Obstructive Pulmonary Disease (COPD). It focuses on validating existing scoring systems, such as the DECAF score and the ROME classification, specifically in Asian populations. By analyzing symptoms, physiological parameters, and laboratory findings, the study seeks to enhance risk stratification for these patients. The ultimate goal is to improve clinical decision-making and patient management during COPD exacerbations.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a confirmed history of COPD who are currently experiencing an exacerbation.
Not a fit: Patients under 18 years old or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better risk stratification and management strategies for patients with COPD exacerbations.
How similar studies have performed: While the DECAF score has been proposed for predicting in-hospital mortality, its validation in Asian populations is novel, and the ROME classification has yet to be prospectively validated, making this approach relatively untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Background history of COPD, defined by the GOLD 2023 guidelines * Presented with exacerbation of COPD, defined by the GOLD 2023 guidelines * Age \>= 18 years old * Informed consent available Exclusion Criteria: * Age \< 18 years old * No informed consent
Where this trial is running
Hong Kong, Other and 1 other locations
- Charles Wong — Hong Kong, Other, Hong Kong (Recruiting)
- Pamela Youde Nethersole Eastern Hospital — Hong Kong, Hong Kong (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.